ACADIA Pharmaceuticals is a biopharmaceutical company developing treatments for neurological and rare diseases in North America. Its marketed products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, alongside a pipeline of candidates in clinical trials targeting conditions such as Alzheimer's psychosis, major depressive disorder, essential tremor, and Huntington's disease. The company operates through licensing agreements with partners including Neuren Pharmaceuticals and Stoke Therapeutics to expand its portfolio of therapies for severe genetic and neurological conditions.
1Y: 18.37 (-23.9%) · range 16.50–30.57
entry readiness 74 · GOOD SETUP · exit proximity 0
Value area 16.16–26.43 · 95% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.700 | Nov 13, 2026 |
| breakdown-signal | 0.694 | Nov 10, 2026 |
Not yet labeled — the study prices these as positions mature.